"Designing Growth Strategies is in our DNA"

U.S. Tardive Dyskinesia Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: July 01, 2024 | Format: PDF | Report ID: FBI107826



Play Audio Listen to Audio Version

The U.S. tardive dyskinesia therapeutics market size was worth USD 2.24 billion in 2022 and is projected to grow at a CAGR of 7.8% during the forecast period. 

The U.S. has witnessed a substantial increase in awareness of Tardive Dyskinesia (TD) among the patient population. The ailment is a type of movement disorder that occurs as a side effect of the long term use of antipsychotics. In May 2022, the Gerontological Advanced Practice Nurses Association (GAPNA) organized the tardive dyskinesia therapeutics awareness program from 1st May – 7th May. Since 2018, the program is conducted every year in collaboration with Neurocrine Biosciences in all the 50 states in the U.S.

The prevalence of this disease is rising due to the usage of antipsychotic drugs in treating schizophrenia, schizoaffective disorder, and bipolar disorder. This is propelling the demand for effective tardive dyskinesia therapeutics measures for this condition. The outbreak of COVID-19 led to slower market growth due to a decline in hospital visits for the diagnosis and treatment of this disease.


Introduction of Innovative Campaigns to Increase Patient Engagement

Many public and private organizations are conducting TD awareness week and introducing software applications to educate people about the symptoms and keep track of these symptoms. For instance, the National Organization for Tardive Dyskinesia (NOTD), a non-profit organization, conducted TD awareness week in 50 states in the U.S. in May 2022. They also launched a smartphone app to track symptoms and chart the progress of any tardive dyskinesia treatment.


Increasing Prevalence of Tardive Dyskinesia to Propel Industry Growth

Patients treated for schizophrenia, schizoaffective disorder, bipolar disorder, and other neurological disorders are most likely to develop persistent and irreversible tardive dyskinesia. Moreover, it is not rare, and anyone exposed to treatment with antipsychotic drugs is at risk, which is one of the critical factors responsible for the growing prevalence of this disease. According to an article published by the BMC Psychiatry Journal in 2020, the prevalence of antipsychotic use among U.S. adults was estimated at 1.7%. Increase in consumption of antipsychotic drug will lead to an increase in demand for tardive dyskinesia therapeutics during the forecast period.


Request a Free sample to learn more about this report.

Lack of Drugs Approved for the Treatment May Restrain Market Growth

The disease has no known cure, but its symptoms can be managed. This includes mental and physical changes such as facial grimacing, rocking or thrusting the pelvis, jaw swinging, and repetitive chewing. Physical symptoms typically include twitching, shaking, or jerking in the hands, feet, face, or torso, which may worsen over time.

There are only two approved vmat2 inhibitors class medications for tardive dyskinesia. These are valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO). Thus, the lack of newly approved drugs to treat this condition limits the treatment options for the patient population. This is subsequently limiting the U.S. tardive dyskinesia therapeutics market growth.

The annual cumulative incidence of tardive dyskinesia is about 4% to 5% and the prevalence rate is 20% to 30% globally.


By Drug Analysis

By drug, the market is segmented into deutetrabenazine, valbenazine, and others.

The valbenazine segment dominated the U.S. tardive dyskinesia therapeutics market share in 2022, owing to strategic initiatives made by the market players to drive the adoption of valbenazine in the country.

  • According to the 2021 annual report of Neurocrine Biosciences, Inc., the company entered INTO distribution agreements for the INGREZZA (valbenazine) with a limited number of specialty pharmacy providers and distributors, which represented approximately 82.0% of INGREZZA product revenue in 2021.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a larger share in the U.S. market in 2022. The dominance of this segment is attributed to the fact that most medications for treatment can only be prescribed by trained medical professionals at hospitals after a thorough examination. The increase in the number of patients seeking treatment for this condition will escalate the demand for early diagnosis and effective treatment options in hospital settings.

  • For instance, as per an article published in the National Alliance on Mental Health (NAMI) in November 2022, Tardive Dyskinesia (TD) affects around 600,000 people in the U.S. However, only 30% of those affected are diagnosed while 70% of individuals potentially living with TD are yet to be diagnosed.


In terms of competitive landscape, Neurocrine Biosciences, Inc. dominated the U.S. market in 2022. The company's apex position is due to the strong sales performance of its approved product, INGREZZA (valbenazine). The company is focused on incorporating the Direct-to-Consumer (DTC) model to increase its customer base and expand its product awareness in the U.S. market.

Some other key tardive dyskinesia therapeutics players with a considerable presence in the U.S. include Teva Pharmaceutical Industries Ltd. and Mitsubishi Tanabe Pharma Corporation. These companies are focusing on increasing patient population awareness through innovative campaigns and product launches. For instance, in April 2021, Teva pushed its marketing strategy by introducing its first consumer campaign for AUSTEDO to reach more people with tardive dyskinesia conditions. Such strategic moves are expected to strengthen the companies' presence in the U.S. market.


  • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation) (Japan)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Neurocrine Biosciences, Inc. (U.S.)

  • SOM BIOTECH (Spain)

  • Luye Pharma Group (China)


  • May 2022 – Neurocrine Biosciences presented findings from a study on using INGREZZA capsules for tardive dyskinesia therapeutics at the American Psychiatric Association (APA). The data showed that taking the medication (40 mg or 80 mg) once a day for 48 weeks led to significant improvements in TD symptoms, as clinicians and patients rated while maintaining stability in psychiatric symptoms.

  • August 2021 – Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd., released the results from a posthoc analysis of a three-year study assessing the effectiveness and safety of AUSTEDO (deutetrabenazine) tablets for treating Tardive Dyskinesia (TD) in patients under 55 and over 55.

  • August 2021 – Luye Pharma Group announced that the new drug application for LY03015, its vesicular monoamine transporter 2 (VMAT2) inhibitor of next generation, used for the treatment in TD was submitted in the U.S. The Phase I clinical trial is expected to commence in the near future.


An Infographic Representation of U.S. Tardive Dyskinesia Therapeutics Market

To get information on various segments, share your queries with us

The market research report provides a detailed analysis of the industry. It focuses on key aspects such as the prevalence of tardive dyskinesia in the U.S. Additionally, it includes an overview of the regulatory and reimbursement scenario for tardive dyskinesia, key industry developments, and the impact of COVID-19 on the market. Besides this, the report offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 7.8% from 2023 to 2030


Value (USD Billion)


By Drug

  • Deutetrabenazine

  • Valbenazine

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Drug Stores & Retail Pharmacies

  • Online Pharmacies

Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 2.24 billion in 2022.

The market is expected to exhibit a CAGR of 7.8% during the forecast period (2023-2030).

By drug, the valbenazine segment holds a leading share in the market.

Neurocrine Biosciences, Inc. and Teva Pharmaceutical Industries Ltd. are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 60

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.